Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation

Natalia Gonzalez Caldito, Shirley O’Leary, Olaf Stuve

Research output: Contribution to journalArticlepeer-review

Abstract

One known adverse event associated with dimethyl fumarate (DMF) is grade III lymphopenia which usually resolves within 2–3 months upon DMF discontinuation. Here, we report a case of a 50-year-old woman with MS who developed grade III lymphopenia within 6 months of DMF initiation, and despite treatment cessation within the next 6 months, she has continued to have severe persistent lymphopenia for over 5 years. Our observation suggests prolonged and possibly irreversible lymphopenia as a possible adverse event of DMF, and it emphasizes the need for monitoring lymphocyte numbers, and to cease dosing promptly after onset of grade III lymphopenia.

Original languageEnglish (US)
Pages (from-to)1306-1308
Number of pages3
JournalMultiple Sclerosis Journal
Volume27
Issue number8
DOIs
StatePublished - Jul 2021
Externally publishedYes

Keywords

  • Tecfidera
  • adverse event
  • dimethyl fumarate
  • lymphopenia
  • pharmacovigilance

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation'. Together they form a unique fingerprint.

Cite this